|  |  |
| --- | --- |
| **eTable 3** Partial correlations between loge sNfL concentrations and immune cell subpopulation frequencies in RRMS patients on highly active treatment, excluding patients treated with fingolimod, at baseline (n=29). | |
|  | **rp/p** |
| Total CD3+ | (-)0.203/0.299/ (-)0.211/0.292 |
| CD3+CD4+ | (-) 0.028/0.886/ (-)0.032/0.873 |
| CD3+CD4+CD25+CD127- (CD4+T-reg) | 0.291/0.133/ 0.310/0.116 |
| CD3+CD8+ | (-)0.298/0.124/ (-)0.305/0.122 |
| CD3+CD8+CD28-CD127- (CD8+T-reg) | (-)0.083/0.673/ (-)0.078/0.697 |
| CD3+CD4+CCR6-CD161-CXCR3+ (Th1) | 0.126/0.523 / 0.111/ 0.582 |
| CD3+CD4+CCR6+CD161+CXCR3-CCR4+ (Th17) | 0.075/0.704/ 0.077/0.701 |
| CD3+CD4+CCR6+CD161+CxCR3highCCR4low (Th1/Th17) | (-)0.012/0.952/ (-)0.012/0.951 |
| Total CD19+ | (-)0.06/0.762/ (-)0.066/0.745 |
| CD19+CD24highCD38low (B-memory) | (-)0.062/0.753/ (-)0.081/0.689 |
| CD19+CD24lowCD38low (B-mature) | 0.169/0.390/ 0.183/0.362 |
| CD19+CD24highCD38high (B-reg) | 0.045/0.818/ 0.031/0.877 |
| CD19+CD24-CD38high (plasma B-cells) | (-)0.264/0.175/ (-)0.254/0.201 |
| CD16+CD56low (CD56 dim NK cells) | 0.214/0.275/ 0.235/0.238 |
| CD16+CD56high (CD56 bright NK cells) | (-)0.262/0.178/ (-)0.267/0.178 |
| Abbreviations: RRMS = relapsing remitting MS; highly active treatment = natalizumab, alemtuzumab, rituximab and ocrelizumab. sNfL= serum neurofilament light chain; rp = partial correlation coefficient; The rp’es are corrected for age and gender. Significant p-values are shown in bold together with the corresponding rp. None of the p-values survived multiple testing. | |